47 results about "Metforminum" patented technology

The invention describes formulations that include either metformin, sulfonylurea or a biguanide-sulfonylurea combination as one active ingredient in addition to specific, other active ingredients. The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of the included biguanide (metformin) and / or sulfonylurea in the prevention and treatment of insulin resistance and diabetes mellitus. The carefully chosen additional active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and those adverse incidences associated with the concurrent use of metformin and / or the sulfonylureas. When clinically administered, the invention will provide therapeutic levels of metformin and of a sulfonylurea, alone or in combination, and broaden their usefulness. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and / or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and / or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

The invention relates to field of natural medicine and medicinal chemistry, in particular to novel pentacyclic triterpene and melbine salt I of the derivative thereof. The salt compound can be used for preparing medicaments curing diabetes mellitus and complicating disease thereof, cerebral ischemia, angiocardiopathy, atherosclerosis, hepatitis, fatty liver and metabolic syndrome or tumour, descendens blood fat drugs and anti-obesity drugs. The invention also relates to the preparation method of the salt compound.

A dosage form for the treatment of diabetes mellitus and conditions associated with it comprising a biguanide such as metformin or its pharmaceutically acceptable salt wherein the metformin is released in a controlled manner. A dosage form for the treatment of diabetes mellitus and conditions associated with it comprising an immediate release composition comprising a long-acting sulfonyl urea and a controlled release composition comprising a biguanide.

The invention discloses a pharmaceutical composition for treating diabetes and controlling diabetic complications and application thereof in pharmaceutics, belonging to the technical field of medicines. The pharmaceutical composition provided in the invention comprises a chemical medicine and a Chinese herbal medicine extract, and specifically comprises metformin hydrochloride and cinnamon extract. The pharmaceutical composition in the invention has a good effect on treating diabetes, can effectively control occurrence of diabetic complications, produces low adverse reaction; the utilization of the pharmaceutical composition is more safe and reliable compared to single utilization of chemical medicines and enables usage amount of metformin hydrochloride to be reduced.

The invention belongs to the field of pharmaceutical compositions for treating non-insulin dependent diabetes mellitus (NIDDM), and in particular relates to a novel pharmaceutical composition for repaglinide and dimethyldiguanide tablets and a preparation method thereof. The pharmaceutical composition is equivalent to PrandiMet in dissolving-out characteristic on the basis that good content uniformity of repaglinide is ensured, and related substances are superior to the existing products. The preparation method is suitable for industrialized production.

The invention provides an application of bergamottin in preparation of medicines for preventing and treating diabetes and preparation of functional foods or health care products for preventing and treating diabetes. The bergamottin has the chemical formula of C21H22O4 and the relative molecular mass of 338.4. Studies prove that the bergamottin shows significant glucose consumption activity in human liver cancer HepG2 cells and has good concentration dependence, the action concentration is far lower than that of a positive medicine, namely metformin, and the efficacy is better than that of metformin. The bergamottin can significantly reduce blood glucose of diabetic KK-Ay mice in diabetic KK-Ay mouse bodies and increase glucose tolerance and insulin sensitivity. The studies about hypoglycemic activity of the bergamottin on intracellular level and in-vivo level show that the bergamottin shows significant hypoglycemic activity, can increase the glucose tolerance and insulin sensitivity and can be used as a treatment medicine or functional food or health care product for preventing and treating diseases related to abnormal glucose metabolism.

The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a pharmaceutical composition comprising metformin and sitagliptin or salts thereof which is glidant and / or surface active agent. The invention also includes process of preparing such compositions and method of use of such compositions for treating type II diabetes.

The invention firstly provides a composition containing a protein kinase inhibitor and metformin or pharmaceutically acceptable salts thereof. The composition is characterized in that the protein kinase inhibitor is one selected from nilotinib, pazopanib, afatinib, bosutinib, crizotinib, axitinib and regorafenib or pharmaceutically acceptable salts or solvates thereof or solvates of the pharmaceutically acceptable salts thereof, and the molar ratio of the metformin to the protein kinase inhibitor is (0.01-100):1. In-vitro bacteriostatic tests find that the composition containing the metforminand the protein kinase inhibitor can achieve a synergistic bacteriostatic effect on various bacteria such as staphylococcus aureus in the molar ratio of (0.01-100):1 (at an inhibition rate of 30%, thecombined medication index CI is smaller than 1).

A dimethyldiguanide salt of a thiazolidinedione pharmaceutical and a preparation method and use thereof are disclosed. The invention provides a salt or adduct or solvent thereof formed by the thiazolidinedione pharmaceutical and dimethyldiguanide via special chemical bonds and corresponding preparation method; further pharmaceutical composition of dimethyldiguanide of the thiazolidinedione pharmaceutical, dimethyldiguanide (adduct) of the thiazolidinedione pharmaceutical or solvent thereof and one or more consistent pharmaceutical preparation or pharmaceutical composition obtained by pharmaceutical or / and carrier or / and excipient optionally. The pharmaceutical preparation or pharmaceutical composition is applied to treating or preventing various diseases by thiazolidinedione pharmaceutical and / or dimethyldiguanide, in particular metabolic syndrome for instance diabetes.

Provided herein are methods for modulating the intestinal microbial profile and for reducing intestinal dysbiosis in type 2 diabetic or pre-diabetic subjects, comprising administering metformin or a derivative or salt thereof and one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii. Also provided are methods for treating type 2 diabetes or an associated metabolic complication or condition and for delaying the onset of type 2 diabetes in pre-diabetic subjects, comprising administering one or more probiotic microorganisms selected from Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus gasseri, Bifidobacterum breve, Bifidobacterium animalis sub sp. lactis, Bifidobacterium bifidum, Streptococcus thermophilus and Saccharomyces boulardii.

The invention relates to sulfonylurea compound and metformin salts, a preparation method and application. The preparation method comprises the following steps: dissolving a sulfonylurea compound and metformin into a solvent according to a mole ratio of (1:0.9):(1:1.1) so as to obtain a mixture; performing reaction crystallization on the mixture under a condition of 25-50 DEG C for 12-48 hours; andperforming solid-liquid phase separation on the obtained product, and performing drying, so as to obtain a salt type solid product. The sulfonylurea compound is gliquidone or glibenclamide. The gliquidone-metformin salt and the glibenclamide-metformin salt provided by the invention are applied to medicines for preventing and treating diabetes. The wet absorption capacities of the salt type products provided by the invention are greatly increased when being compared with that of metformin, that is, the hygroscopy gain of the metformin is 35% when the relative humidity is 75%, and the hygroscopy gains of the salt type products are smaller than 1%; and the dissolubility of the salt type products is greatly improved when being compared with that of the sulfonylurea compound, that is, the dissolubility of the sulfonylurea compound in water is smaller than 0.03mg / ml, and the dissolubility after salt formation is 10.61mg / ml and 16.78mg / ml respectively.

The present invention discloses a marker for determining a treatment plan for colorectal cancer. The marker is a KRAS gene and / or protein. For KRAS mutant type colorectal cancer, metformin is used totreat the colorectal cancer. For the first time, use of the metformin in patients with the KRAS mutant type colorectal cancer is determined to have more significant benefits, down-regulation of META1expression in a metformin discharge channel is further determined to be a key mechanism for KRAS mutant colorectal cancer cells to be sensitive to the metformin, a transcription level of META1 is reduced to increase concentration of the metformin in tumor cells, and thus an effect of the metformin on inhibiting tumor cell proliferation is enhanced. A novel idea and method for the treatment of thecolorectal cancer are provided, have far-reaching significance and are deserved to be vigorously promoted.

The application provides a mesenchymal stem cell preparation for treating arthritis. The mesenchymal stem cell preparation comprises mesenchymal stem cells, metformin-pretreated mesenchymal stem cells, platelet-enriched blood plasma and a dispersing medium. The metformin-pretreated mesenchymal stem cells can be used for improving osteogenesis differentiation capability of the mesenchymal stem cells and facilitating injury restoration. By using the mesenchymal stem cells and the metformin-pretreated mesenchymal stem cells in a mixed manner, secretion of anti-inflammatory factors of the mesenchymal stem cells can be guaranteed, and the tissue restorability of the mesenchymal stem cells can also be guaranteed. The mesenchymal stem cell preparation provided by the invention is applicable to inflammation relieving and impaired tissue restoration of an osteoarthritis disease and can achieve symptom relieving and function recovery of a sufferer.

The invention relates to a medicinal composition for treating diabetes, and its application in the preparation of medicines for treating the diabetes. The medicinal composition comprises glycine and metformin hydrochloride, and the best mass ratio of glycine to metformin hydrochloride is 3:1, 4:1 or 5:1. The cooperation of glycine and metformin hydrochloride realizes a reinforced effect or a synergistic effect, so the use effect of the medicinal composition can be improved. The administration concentrations of glycine and metformin hydrochloride are reduced on the premise that a same treatment effect is obtained, so the generation risk of adverse reactions is reduced.

The invention provides an application of an AMPK activator in the preparation of a product for improving an abnormal AMPK signaling pathway in bone marrow mesenchymal stem cells. In-vitro experimentsprove that the osteogenic differentiation capacity of bone marrow mesenchymal stem cells derived from patients with hypophosphatasia or ALPL knockout mice is abnormal, a signal channel protein chip finds that the intracellular AMPK protein phosphorylation of the bone marrow mesenchymal stem cells with the abnormal osteogenic differentiation capacity is remarkably reduced, and the AMPK activator metformin is used to act on the bone marrow mesenchymal stem cells with the abnormal osteogenic differentiation capacity, so that a blocked downstream pathway is restarted, and thereby the osteogenic differentiation characteristic of the bone marrow mesenchymal stem cells with the abnormal osteogenic differentiation capacity is recovered.

The invention relates to a metformin hydrochloride and glibenclamide composition. The metformin hydrochloride and glibenclamide composition is prepared from, by weight, 1.25-2.5mg of glibenclamide, 250-500mg of metformin hydrochloride, 250-500mg of hydroxypropyl methylcellulose acetate succinate, 3-5mg of sodium hydroxide and 12.5-25mg of low-substituted hydroxypropyl cellulose. The metformin hydrochloride and glibenclamide composition further comprises an adjuvant. The invention further discloses a preparation method. The metformin hydrochloride and glibenclamide composition has the advantages of being high in dissolution rate, few in impurity and high in effective medicine content.

The invention provides a method for improving the osteogenesis ability of mesenchymal stem cells, which comprises the following steps: inoculating the mesenchymal stem cells into an alpha-MEM culturemedium containing 10% of fetal calf serum, culturing, digesting and subculturing by 0.2% of pancreatin when the fusion degree of the mesenchymal stem cells is 80-85%, inoculating the obtained mesenchymal stem cells into an alpha-MEM culture medium containing 10% of fetal calf serum for culture, and adding osteogenesis induction liquid and a metformin aqueous solution for induction when the densityof the mesenchymal stem cells is greater than 90% for induction for 14-21 days. The metformin acts on the mesenchymal stem cells, alizarin red staining results show that the metformin can significantly improve the calcium mineralization nodule degree of the cells, and it is indicated that the metformin has a significant induction effect on mesenchymal stem cell osteogenic differentiation, the metformin can significantly improve the expression of the mesenchymal stem cell osteogenic differentiation related genes SIRT1, ALP, COL1A1, RUNX2 and BGLAP, and the improvement of the osteogenic differentiation capacity of the mesenchymal stem cells is of great significance to stem cell transplantation and bone biology research.

The invention relates to an application of stomach-regulating qi-supporting decoction in preparation of a medicine for preventing and treating metabolic syndrome caused by olanzapine taken by schizophrenia patients. Clinical experiments prove that the curative effect and safety of the stomach-regulating qi-supporting decoction for treating metabolic syndrome caused by taking olanzapine by schizophrenia patients are evaluated; results show that compared with metformin, the stomach-regulating qi-supporting decoction can better improve weight and waistline increase caused by taking olanzapine byschizophrenia patients, reduce glycosylated hemoglobin and reduce side effects; the stomach-regulating qi-supporting decoction has a prevention effect on disorder of various indexes of blood fat caused by taking olanzapine. The invention provides a new effective means for preventing and treating metabolic syndrome caused by taking olanzapine by clinical schizophrenia patients.

A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4 / CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.

The invention discloses an application of a pharmaceutical composition of metformin and an anti-PD-1 antibody in preparation of a liver cancer drug. According to the invention, immunohistochemical staining is carried out on a tissue sample of a liver cancer patient, and the expression level of PSPH marker protein molecules in liver cancer nest tissue in liver cancer tissue is detected and analyzed; and combined medication of metformin and the anti-PD-1 antibody for PSPH positive patients are guided, and the purpose of improving treatment effect is achieved. When the combined medication of metformin and the anti-PD-1 antibody for patients with high PSPH expression has far better treatment effect than the treatment effect of independent medication of only one selected from metformin and the anti-PD-1 antibody, so precise treatment is achieved, and good treatment effect is achieved.

The invention belongs to the technical field of biological pharmacy, and relates to a novel nano gene drug for non-alcoholic fatty liver disease and a preparation method thereof. The nano gene drug for non-alcoholic fatty liver disease is formed by taking metformin grafted chitosan, a cell-penetrating agent and DSPE-PEG2000 as carriers and carrying out self-assembly on the carriers and an anion treatment gene. The metformin grafted chitosan in the nano gene drug can have high transfection efficiency and protect the intrinsic pharmacological activity of the non-alcoholic fatty liver disease atthe same time. The nano gene drug can effectively target the liver part, and a treatment effect is achieved by overexpression or interference of synthesis of certain key proteins. The nano gene drug prepared by the invention has the characteristics of high safety, good stability and controllable quality. The nano gene drug can effectively treat non-alcoholic fatty liver diseases and obesity-related metabolic syndrome, and is expected to become a drug for protecting liver injury and regulating metabolic-related diseases.

The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases or disorders associated with elevated or increased ceramide levels. Pharmaceutical formulations comprising metformin glycinate are also disclosed.

The invention relates to a method and composition for use in treating a condition that benefits from the reduction of hepatic and / or visceral fat, such as polycystic ovary syndrome in adolescent girlsor women of childbearing age, involving the use of spironolactone, pioglitazone and metformin.